A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer

European Journal of Cancer

Volumn 34, Issue 6, 1998, Pages 820-824

  Coleman, R E ^a   Houston, S ^b   Purohit, O P ^a   Rubens, R D ^b   Kandra, A ^c   Ford, J ^c  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bone metastases; Breast cancer; Oral pamidronate

Indexed keywords

PAMIDRONIC ACID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; PAIN; VOMITING;

EID: 0032078278     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10155-1     Document Type: Article

References (15)

1. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996, 335, 1785-1791.
2. Paterson AHG, Powles TJ, Kanis JA, et al. Double blind controlled trial of clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11, 59-65.
3. Berenson JR., Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334, 488-493.
4. Lahtinen R, Laakso M, Palva I, et al. for the Finnish Leukaemia Group. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992, 340, 1049.
5. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994, 70, 554-558.
6. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate. Results from a multinational randomised controlled trial. J Clin Oncol 1996, 14, 2552-2559.
7. Body J-J, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treatment Rev 1996, 22, 265-287.
8. Holten-Verzantvoort AT van, Kroon HM, Bijvoet OLM, et al. Palliative bone treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11, 491-498.
9. Rose C, Ford J, Becher R, et al. on behalf of the Aredia international Study Group. Pamidronate disodium (Aredia), dose effect and tolerability evaluation in breast cancer patients with bone metastases, ESMO proceedings. Ann Oncol 1992, 3(Suppl. 5), 85.
10. Fairbank JCT, Couper J, Davies JB, O'Brien JP. The Oswestry low back questionnaire. Physiotherapy 1980, 66, 271-273.
11. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Eur J Cancer Clin Oncol 1977, 13, 89-94.
12. Ernst DS, MacDonald RN, Paterson AHG, Jensen J, Bruera E. A double-blind cross-over trial of IV clodronate in metastatic bone pain. J Pain Sympt Manag 1992, 7, 4-11.
13. Holten-Verzantvoort ATM van, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11, 491-498.
14. Coleman RE, Purohit OP, Black C, et al. Ibandronate: a well tolerated new oral bisphosphonate for the treatment of bone metastases. The Breast 1995, 4(3), 236.
15. De Groen PC, Lubbe DF, Hirsch LJ, et al. Oesophagitis associated with the use of alendronate. N Engl J Med 1996, 335, 1016, 1021.